Ken Fallin is a notable inventor based in Diamondhead, MS (US), recognized for his contributions to the field of pharmaceuticals. With a total of four patents to his name, he has made significant advancements in the formulation of drug suspensions.

Latest Patents

Among his latest patents is a composition and method for proton pump inhibitor suspension. This innovation involves suspensions of pump inhibitors (PPIs) that may include a PPI, a copolymer of ethylene oxide and propylene oxide, simethicone emulsion, sodium bicarbonate, and sodium citrate, USP (Dihydrate). These suspensions are designed to have desirable viscosities and enhanced stability. Another notable patent involves suspensions and diluents for metronidazole and baclofen. This patent discloses suspensions that may include metronidazole or baclofen, along with a hydrocolloid stabilizer, simethicone emulsion, a buffer such as sodium citrate (dihydrate), a preservative, a thickening agent, a sweetener, and water.

Career Highlights

Ken Fallin is currently employed at Azurity Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on improving the stability and efficacy of drug formulations, which is crucial for patient care.

Collaborations

He collaborates with talented coworkers such as Neal Muni and Kaity Renaud, contributing to a dynamic team environment that fosters innovation.

Conclusion

Ken Fallin's work in pharmaceutical suspensions exemplifies the impact of innovation in medicine. His patents not only enhance drug formulations but also improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.